Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study
Marlies S Wijsenbeek, Elisabeth Bendstrup, Claudia Valenzuela, Michael T Henry, Catharina C Moor, Stéphane Jouneau, Alessandro G Fois, Onofre Moran-Mendoza, Syed Anees, Mirela Mirt, Monica Bengus, Frank Gilberg, Klaus-Uwe Kirchgaessler, Carlo Vancheri, Marlies S Wijsenbeek, Elisabeth Bendstrup, Claudia Valenzuela, Michael T Henry, Catharina C Moor, Stéphane Jouneau, Alessandro G Fois, Onofre Moran-Mendoza, Syed Anees, Mirela Mirt, Monica Bengus, Frank Gilberg, Klaus-Uwe Kirchgaessler, Carlo Vancheri
Abstract
Introduction: Disease behaviour may guide diagnosis and treatment decisions in patients with interstitial lung disease (ILD). STARLINER aimed to characterise disease behaviour in patients with suspected ILD during the peri-diagnostic period using real-time home-based assessments.
Methods: STARLINER (NCT03261037) was an international, multicentre study. Patients ≥ 50 years old with suspected ILD were followed throughout the peri-diagnostic period, consisting of a pre-diagnostic period (from enrolment to diagnosis) and a post-diagnostic period (from diagnosis to treatment initiation). Study length was variable (≤ 18 months). The primary endpoint was time-adjusted semi-annual forced vital capacity (FVC) change measured during the peri-diagnostic period using daily home spirometry in patients with idiopathic pulmonary fibrosis (IPF). Secondary outcomes included changes in FVC (home spirometry) in patients with non-IPF ILD, changes in FVC (site spirometry), changes in physical functional capacity measured by daily home accelerometry and site 6-min walk distance (6MWD), and changes in patient-reported outcomes (PROs) in IPF or non-IPF ILD.
Results: Of the 178 patients enrolled in the study, 68 patients were diagnosed with IPF, 62 patients were diagnosed with non-IPF ILD, 9 patients received a non-ILD diagnosis and 39 patients did not receive a diagnosis. Technical and analytical issues led to problems in applying the prespecified linear regression model to analyse the home FVC data. Time-adjusted median (quartile [Q]1, Q3) semi-annual FVC change during the peri-diagnostic period measured using home and site spirometry, respectively, was - 147.7 (- 723.8, 376.2) ml and - 149.0 (- 314.6, 163.9) ml for IPF and 19.1 (- 194.9, 519.0) ml and - 23.4 (- 117.9, 133.5) ml in non-IPF ILD. A greater decline in steps per day was observed for IPF versus non-IPF ILD, whereas an increase in 6MWD was observed for patients with IPF versus a decline in 6MWD for patients with non-IPF ILD. No clear patterns of disease behaviour were observed for IPF versus non-IPF ILD for PROs.
Conclusions: Despite home spirometry being feasible for most patients and centres, technical and analytical challenges in the home-based assessments prevented firm conclusions regarding disease behaviour. This highlights that further optimisation of the technology and analysis methods is required before widespread implementation.
Trial registration: NCT03261037.
Keywords: Disease behaviour; Home spirometry; Idiopathic pulmonary fibrosis; Interstitial lung disease; Peri-diagnostic period.
© 2021. The Author(s).
Figures
References
- Ryerson CJ, Collard HR. Update on the diagnosis and classification of ILD. Curr Opin Pulm Med. 2013;19:453–459. doi: 10.1097/MCP.0b013e328363f48d.
- Gibson GJ. Interstitial lung diseases. In: Gibson GJ, Loddenkemper R, Sibille Y, Lundbäck B, Fletcher M, editors. European Lung White Book. 2. Sheffield: European Respiratory Society; 2013. pp. 256–269.
- Cottin V, Hirani NA, Hotchkin DL, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27:180076. doi: 10.1183/16000617.0076-2018.
- Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–2082. doi: 10.1056/NEJMoa1402584.
- Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760–1769. doi: 10.1016/S0140-6736(11)60405-4.
- King TE, Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–2092. doi: 10.1056/NEJMoa1402582.
- Fernandez Perez ER, Swigris JJ, Forssen AV, et al. Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest. 2013;144:1644–1651. doi: 10.1378/chest.12-2685.
- Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380:2518–2528. doi: 10.1056/NEJMoa1903076.
- Maher TM, Wuyts W. Management of fibrosing interstitial lung diseases. Adv Ther. 2019;36:1518–1531. doi: 10.1007/s12325-019-00992-9.
- Russell AM, Ripamonti E, Vancheri C. Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients' perspectives of the disease and treatment. BMC Pulm Med. 2016;16:10. doi: 10.1186/s12890-016-0171-y.
- Cosgrove GP, Bianchi P, Danese S, Lederer DJ. Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey. BMC Pulm Med. 2018;18:9. doi: 10.1186/s12890-017-0560-x.
- Lamas DJ, Kawut SM, Bagiella E, Philip N, Arcasoy SM, Lederer DJ. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med. 2011;184:842–847. doi: 10.1164/rccm.201104-0668OC.
- Wells AU. Managing diagnostic procedures in idiopathic pulmonary fibrosis. Eur Respir Rev. 2013;22:158–162. doi: 10.1183/09059180.00001213.
- Bonella F, Wijsenbeek M, Molina-Molina M, et al. European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers. Eur Respir J. 2016;47:597–606. doi: 10.1183/13993003.01204-2015.
- Hoyer N, Prior TS, Bendstrup E, Wilcke T, Shaker SB. Risk factors for diagnostic delay in idiopathic pulmonary fibrosis. Respir Res. 2019;20:103. doi: 10.1186/s12931-019-1076-0.
- Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med. 2018;6:138–153. doi: 10.1016/S2213-2600(17)30433-2.
- Wijsenbeek M, Bendstrup E, Valenzuela C, et al. Design of a study assessing disease behaviour during the peri-diagnostic period in patients with interstitial lung disease: the STARLINER Study. Adv Ther. 2019;36:232–243. doi: 10.1007/s12325-018-0845-3.
- Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8:147–157. doi: 10.1016/S2213-2600(19)30341-8.
- Hegewald MJ, Gallo HM, Wilson EL. Accuracy and quality of spirometry in primary care offices. Ann Am Thorac Soc. 2016;13:2119–2124. doi: 10.1513/AnnalsATS.201605-418OC.
- Walters JA, Wood-Baker R, Walls J, Johns DP. Stability of the EasyOne ultrasonic spirometer for use in general practice. Respirology. 2006;11:306–310. doi: 10.1111/j.1440-1843.2006.00842.x.
- Nakshbandi G, Moor CC, Wijsenbeek MS. Home monitoring for patients with ILD and the COVID-19 pandemic. Lancet Respir Med. 2020;8:1172–1174. doi: 10.1016/S2213-2600(20)30452-5.
- Moor C, Mostard RLM, Grutters JC, et al. Home monitoring in patients with idiopathic pulmonary fibrosis: a randomized controlled trial. Am J Respir Crit Care Med. 2020;202:393–401. doi: 10.1164/rccm.202002-0328OC.
- Moor CC, van Manen MJG, Tak NC, van Noort E, Wijsenbeek MS. Development and feasibility of an eHealth tool for idiopathic pulmonary fibrosis. Eur Respir J. 2018;51:1702508. doi: 10.1183/13993003.02508-2017.
- Moor CC, Wapenaar M, Miedema JR, Geelhoed JJM, Chandoesing PP, Wijsenbeek MS. A home monitoring program including real-time wireless home spirometry in idiopathic pulmonary fibrosis: a pilot study on experiences and barriers. Respir Res. 2018;19:105. doi: 10.1186/s12931-018-0810-3.
- Swigris S, Nathan S, Tighe R, et al. STARMAP: an observational study to assess disease-relevant outcomes using home-monitoring devices in patients with idiopathic pulmonary fibrosis (IPF) Eur Respir J. 2019;54(Suppl 63):PA1333.
- Johannson KA, Vittinghoff E, Morisset J, Lee JS, Balmes JR, Collard HR. Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis. Eur Respir J. 2017;50:1602406. doi: 10.1183/13993003.02406-2016.
- Wong AW, Fidler L, Marcoux V, et al. Practical considerations for the diagnosis and treatment of fibrotic interstitial lung disease during the coronavirus disease 2019 pandemic. Chest. 2020;158:1069–1078. doi: 10.1016/j.chest.2020.04.019.
- Khan F, Stewart I, Howard L, et al. The Its Not JUST Idiopathic pulmonary fibrosis Study (INJUSTIS): description of the protocol for a multicentre prospective observational cohort study identifying biomarkers of progressive fibrotic lung disease. BMJ Open Respir Res. 2019;6:e000439. doi: 10.1136/bmjresp-2019-000439.
- Tsai APY, Hur SA, Wong A, et al. Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease. Thorax. 2020;76:37–43. doi: 10.1136/thoraxjnl-2020-214944.
- Prior TS, Hoyer N, Hilberg O, Shaker SB, Davidsen JR, Bendstrup E. Responsiveness and minimal clinically important difference of SGRQ-I and K-BILD in idiopathic pulmonary fibrosis. Respir Res. 2020;21:91. doi: 10.1186/s12931-020-01359-3.
- Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733–748. doi: 10.1164/rccm.201308-1483ST.
Source: PubMed